Scalper1 News
Biotech United Therapeutics (UTHR) received Food and Drug Administration approval for its first cancer drug Tuesday and was also awarded a priority-review voucher, which could turn out to be just as lucrative. The agency approved Unituxin, a monoclonal antibody that treats an ultra-rare childhood cancer called neuroblastoma. With only about 650 new cases a year, consensus estimates expect only $73 million in annual sales from the drug by 2019. To Scalper1 News
Scalper1 News